Free Trial
NASDAQ:IMTX

Immatics Q1 2025 Earnings Report

Immatics logo
$5.01 +0.01 (+0.20%)
Closing price 05/1/2025 04:00 PM Eastern
Extended Trading
$5.01 +0.00 (+0.10%)
As of 05/1/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immatics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.39
Beat/Miss
N/A
One Year Ago EPS
N/A

Immatics Revenue Results

Actual Revenue
N/A
Expected Revenue
$14.92 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Immatics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Tuesday, May 13, 2025
Conference Call Time
7:00AM ET

Conference Call Resources

Immatics Earnings Headlines

Watch This Robotics Demo Before July 23rd
Jeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry."
See More Immatics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Immatics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immatics and other key companies, straight to your email.

About Immatics

Immatics (NASDAQ:IMTX) N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

View Immatics Profile

More Earnings Resources from MarketBeat